GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: August 28, 2003, 18:21:02 ; Search time 37.0909 Seconds
(without alignments)
51.353 Million cell updates/sec

Title: US-09-743-225-8
Perfect score: 58
Sequence: 1 NTLKTPRVGGXA 12

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 1107863 seqs, 158726573 residues

Total number of hits satisfying chosen parameters: 1107863

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : A_Geneseq_19Jun03:*
1: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1980.DAT:*
2: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1981.DAT:*
3: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1982.DAT:*
4: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1983.DAT:*
5: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1984.DAT:*
6: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1985.DAT:*
7: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1986.DAT:*
8: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1987.DAT:*
9: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1988.DAT:*
10: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1989.DAT:*
11: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1990.DAT:*
12: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1991.DAT:*
13: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1992.DAT:*
14: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1993.DAT:*
15: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1994.DAT:*
16: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1995.DAT:*
17: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1996.DAT:*
18: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1997.DAT:*
19: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1998.DAT:*
20: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA1999.DAT:*
21: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2000.DAT:*
22: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2001.DAT:*
23: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2002.DAT:*
24: /SIDS1/gcgdata/geneseq/geneseqp-embl/AA2003.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	56	96.6	12	21	AAY69259	Monopeptide which
2	53	91.4	10	21	AAY69268	Peptide which inhi
3	53	91.4	11	21	AAB17990	Beta-2GPI Ab bindi
4	53	91.4	11	23	ABB73361	Exemplary pharmaco
5	41	70.7	8	21	AAB17989	Beta-2GPI Ab bindi
6	41	70.7	8	23	ABB73360	Exemplary pharmaco
7	38	65.5	372	24	ABP77111	N. gonorrhoeae ami
8	37	63.8	68	20	AAY11550	Human 5' EST secre
9	37	63.8	82	20	AAY11742	Human 5' EST secre
10	37	63.8	388	23	ABP66299	Bifidobacterium lo
11	36	62.1	92	22	AAU48931	Propionibacterium
12	36	62.1	140	22	AAM93750	Human polypeptide,
13	36	62.1	256	23	ABB54460	Lactococcus lactis
14	36	62.1	319	21	AAG06393	Arabidopsis thalia
15	36	62.1	323	21	AAG06392	Arabidopsis thalia
16	36	62.1	330	22	AAU41960	Propionibacterium
17	36	62.1	1002	21	AAB23854	Haemophilus influe
18	36	62.1	1301	23	ABB77633	AmEPV fifth RNA po
19	35	60.3	58	22	AAM84843	Human immune/haema
20	35	60.3	144	22	AAM86368	Human immune/haema
21	35	60.3	200	23	AAM49451	Escherichia coli D
22	35	60.3	234	22	ABG08877	Novel human diagno
23	35	60.3	332	21	AAG14804	Arabidopsis thalia
24	35	60.3	332	21	AAG48466	Arabidopsis thalia
25	35	60.3	364	14	AAR39215	Mutant PDG encoded
26	35	60.3	365	14	AAR39214	Mutant PDG encoded
27	35	60.3	367	21	AAG14803	Arabidopsis thalia
28	35	60.3	367	21	AAG48465	Arabidopsis thalia
29	35	60.3	374	14	AAR39221	Mutant PDG encoded
30	35	60.3	395	14	AAR39218	Mutant PDG encoded
31	35	60.3	403	14	AAR39220	Mutant PDG encoded
32	35	60.3	404	14	AAR39222	Mutant PDG encoded
33	35	60.3	405	14	AAR39213	Mutant PDG encoded
34	35	60.3	410	14	AAR39212	E. coli phosphogly
35	35	60.3	410	15	AAR50093	Wild-type phosphog
36	35	60.3	410	22	AAU34698	E. coli cellular p
37	35	60.3	411	14	AAR39219	Mutant PDG encoded
38	35	60.3	412	14	AAR39217	Mutant PDG encoded
39	35	60.3	414	14	AAR39216	Mutant PDG encoded
40	35	60.3	456	21	AAG14802	Arabidopsis thalia
41	35	60.3	456	21	AAG48464	Arabidopsis thalia
42	35	60.3	884	22	ABG22489	Novel human diagno
43	35	60.3	884	22	ABG30084	Novel human diagno
44	35	60.3	1072	22	ABG04157	Novel human diagno
45	34	58.6	84	22	AAO01684	Human polypeptide

ALIGNMENTS

RESULT 1
AAY69259
ID AAY69259 standard; peptide; 12 AA.
XX
AC AAY69259;
XX
DT 30-MAY-2000 (first entry)
XX
DE Monopeptide which inhibits anti-beta-2-glycoprotein 1 antibodies.
XX
KW Anti-beta-2-glycoprotein 1 antibody; anti-B2GPI antibody;
KW anti-phospholipid syndrome; anti-phospholipid antibody;
KW pregnancy complication; thrombosis; coagulation dysregulation.
XX
OS Synthetic.
XX
FH Key Location/Qualifiers
FT Modified-site 11
FT /note= "FmocLys(Fmoc)-OH"
XX
PN WO200001729-A2.
XX
PD 13-JAN-2000.
XX
PF 06-JUL-1999; 99WO-IL00366.
XX
PR 07-JUL-1998; 98IL-0125262.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Blank M, Cabilly S, Shoenfeld Y, Katchalski-Katzir E;
XX

DR WPI; 2000-182105/16.
XX
PT Novel synthetic peptides that inhibit anti-beta-2-glycoprotein 1
PT antibodies, useful for diagnosis and treatment of anti-phospholipid
PT syndrome in humans -
XX
PS Disclosure; Page 13; 58pp; English.
XX
CC The present sequence represents a synthetic peptide which is capable
CC of inhibiting the biological activity of anti-beta-2-glycoprotein 1
CC (B2GPI) monoclonal antibodies in vitro and of inhibiting in vivo
CC induction of experimental anti-phospholipid syndrome in mice by
CC anti-B2GPI monoclonal antibodies. The peptides are used for diagnosis
CC and treatment of anti-phospholipid syndrome. They may also be used
CC for the diagnosis of anti-phospholipid antibodies with different
CC pathogenic biofunctions which may correlate with either pregnancy
CC complications, thrombosis or coagulation dysregulation.
XX
SQ Sequence 12 AA;

Query Match 96.6%; Score 56; DB 21; Length 12;
Best Local Similarity 100.0%; Pred. No. 0.00069;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NTLKTPRVGGXA 12
||||||||||||
Db 1 NTLKTPRVGGXA 12

RESULT 2
AAY69268
ID AAY69268 standard; peptide; 10 AA.
XX
AC AAY69268;
XX
DT 30-MAY-2000 (first entry)
XX
DE Peptide which inhibits anti-beta-2-glycoprotein 1 antibodies.
XX
KW Anti-beta-2-glycoprotein 1 antibody; anti-B2GPI antibody;
KW anti-phospholipid syndrome; anti-phospholipid antibody;
KW pregnancy complication; thrombosis; coagulation dysregulation.
XX
OS Synthetic.
XX
PN WO200001729-A2.
XX
PD 13-JAN-2000.
XX
PF 06-JUL-1999; 99WO-IL00366.
XX
PR 07-JUL-1998; 98IL-0125262.
XX
PA (YEDA) YEDA RES & DEV CO LTD.
XX
PI Blank M, Cabilly S, Shoenfeld Y, Katchalski-Katzir E;
XX
DR WPI; 2000-182105/16.
XX
PT Novel synthetic peptides that inhibit anti-beta-2-glycoprotein 1
PT antibodies, useful for diagnosis and treatment of anti-phospholipid
PT syndrome in humans -
XX
PS Claim 3; Page 37; 58pp; English.
XX
CC The present sequence represents a synthetic peptide which is capable
CC of inhibiting the biological activity of anti-beta-2-glycoprotein 1
CC (B2GPI) monoclonal antibodies in vitro and of inhibiting in vivo
CC induction of experimental anti-phospholipid syndrome in mice by
CC anti-B2GPI monoclonal antibodies. The peptides are used for diagnosis
CC and treatment of anti-phospholipid syndrome. They may also be used
CC for the diagnosis of anti-phospholipid antibodies with different
CC pathogenic biofunctions which may correlate with either pregnancy
CC complications, thrombosis or coagulation dysregulation.
XX
SQ Sequence 10 AA;

Query Match 91.4%; Score 53; DB 21; Length 10;
Best Local Similarity 100.0%; Pred. No. 0.0021;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NTLKTPRVGG 10
||||||||||
Db 1 NTLKTPRVGG 10

RESULT 3
AAB17990
ID AAB17990 standard; Peptide; 11 AA.
XX
AC AAB17990;
XX
DT 31-OCT-2000 (first entry)
XX
DE Beta-2GPI Ab binding peptide sequence SEQ ID NO:1102.
XX
KW Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
KW autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
KW immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
KW MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
KW cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
KW vascular endothelial growth factor; matrix metalloproteinase;
KW asthma; thrombosis; pharmaceutical.
XX
OS Synthetic.
XX
PN WO200024782-A2.
XX
PD 04-MAY-2000.
XX
PF 25-OCT-1999; 99WO-US25044.
XX
PR 23-OCT-1998; 98US-0105371.
PR 22-OCT-1999; 99US-0428082.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham J, Boone TC;
XX
DR WPI; 2000-350702/30.
XX
PT Novel composition of matter comprising an Fc domain and
PT pharmacologically active peptides, useful for treating cancer and
PT autoimmune diseases -
XX
PS Claim 39; Page 599; 608pp; English.
XX
CC The present invention describes composition of matter (I) comprising an
CC Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
CC (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
CC independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
CC -(L1)c-P1-(L2)d-P2-(L3)e-P^3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
CC where P1, P2, P3, and P4 = are each independently sequences of
CC pharmacologically active peptides; L1, L2, L3, and L4 = are each
CC independently linkers; and a, b, c, d, e, and f = are each independently
CC 0 or 1, provided that at least 1 of a and b is 1. The composition can
CC have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
CC activities. DNAs, vectors and host cells from the present invention can
CC be used for producing pharmaceutical compositions. The compositions are
CC useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
CC The use of an Fc domain (rather than a Fab domain) can provide a longer
CC half-life or incorporate functions such as Fc receptor binding, protein
CC A binding, complement fixation, and possibly placental transfer. AAA69443
CC to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid
CC sequences used in the exemplification of the present invention.
XX

SQ Sequence 11 AA;

Query Match 91.4%; Score 53; DB 21; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.0023;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NTLKTPRVGG 10
||||||||||
Db 1 NTLKTPRVGG 10

RESULT 4
ABB73361
ID ABB73361 standard; Peptide; 11 AA.
XX
AC ABB73361;
XX
DT 05-APR-2002 (first entry)
XX
DE Exemplary pharmacologically active peptide SEQ ID NO:1100.
XX
KW Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;
KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
KW cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;
KW antianaemic; anorectic; antiinfertility; haemostatic; dermatological;
KW neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
KW sleep disorder; neurological degenerative disease; anaemia;
KW thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
KW Fanconi's syndrome.
XX
OS Synthetic.
XX
PN WO200183525-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US14310.
XX
PR 03-MAY-2000; 2000US-0563286.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;
XX
DR WPI; 2002-130313/17.
XX
PT Novel vehicle-peptide molecule or its multimers useful for treating
PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
PT diabetic retinopathy, obesity, sleep disorders and infertility -
XX
PS Claim 39; Page 62; 176pp; English.
XX
CC The present invention describes a vehicle-peptide molecule (I) or its
CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
CC cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
CC antianaemic, anorectic, antiinfertility, haemostatic, dermatological and
CC neuroprotective activities. (I) can be used as a therapeutic or
CC prophylactic agent as well as for screening purposes. (I) is useful for
CC diagnosing diseases characterised by dysfunction of their associated
CC protein of interest, for identifying normal or abnormal proteins of
CC interest, as a part of diagnostic kit to detect the presence of their
CC proteins of interest in a biological sample. Additionally, (I) is useful
CC for treating inflammatory and autoimmune diseases, tumour growth, cancer,
CC rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
CC infertility, and neurological degenerative diseases. (I), comprising
CC EPO-mimetic compounds are useful for treating disorders characterised by
CC low red blood cell levels such as anaemia. The TPO-mimetic comprising
CC compounds are useful for treating conditions that involve an existing
CC megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
CC deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
CC tumour which result in thrombocytopaenia, systemic lupus erythematosus,
CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
CC represent amino acid and nucleic acid sequences used in the
CC exemplification of the present invention.
XX
SQ Sequence 11 AA;

Query Match 91.4%; Score 53; DB 23; Length 11;
Best Local Similarity 100.0%; Pred. No. 0.0023;
Matches 10; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NTLKTPRVGG 10
||||||||||
Db 1 NTLKTPRVGG 10

RESULT 5
AAB17989
ID AAB17989 standard; Peptide; 8 AA.
XX
AC AAB17989;
XX
DT 31-OCT-2000 (first entry)
XX
DE Beta-2GPI Ab binding peptide sequence SEQ ID NO:1101.
XX
KW Modified peptide; therapeutic agent; fusion; Fc domain; cancer;
KW autoimmune disease; cytostatic; antiasthmatic; thrombolytic; VEGF;
KW immunosuppressive; EPO; TPO; CTLA4; mimetic; IL-1; TNF; antagonist;
KW MMP; inhibitor; erythropoietin; thrombopoietin; interleukin 1;
KW cytotoxic T cell lymphocyte antigen 4; tumour necrosis factor;
KW vascular endothelial growth factor; matrix metalloproteinase;
KW asthma; thrombosis; pharmaceutical.
XX
OS Synthetic.
XX
PN WO200024782-A2.
XX
PD 04-MAY-2000.
XX
PF 25-OCT-1999; 99WO-US25044.
XX
PR 23-OCT-1998; 98US-0105371.
PR 22-OCT-1999; 99US-0428082.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham J, Boone TC;
XX
DR WPI; 2000-350702/30.
XX
PT Novel composition of matter comprising an Fc domain and
PT pharmacologically active peptides, useful for treating cancer and
PT autoimmune diseases -
XX
PS Claim 39; Page 599; 608pp; English.
XX
CC The present invention describes composition of matter (I) comprising an
CC Fc domain, pharmacologically active peptides, and linkers. Where (I) is:
CC (X1)a-F1-(X2)b, where: F1 = an Fc domain; X1 and X2 = are each
CC independently selected from -(L1)c-P1, -(L1)c-P1-(L2)d-P2,
CC -(L1)c-P1-(L2)d-P2-(L3)e-P^3, or -(L1)c-P1-(L2)d-P2-(L3)e-P3-(L4)f-P4
CC where P1, P2, P3, and P4 = are each independently sequences of
CC pharmacologically active peptides; L1, L2, L3, and L4 = are each
CC independently linkers; and a, b, c, d, e, and f = are each independently
CC 0 or 1, provided that at least 1 of a and b is 1. The composition can
CC have cytostatic, antiasthmatic, thrombolytic and immunosuppressive
CC activities. DNAs, vectors and host cells from the present invention can
CC be used for producing pharmaceutical compositions. The compositions are
CC useful for treating cancer, asthma, thrombosis, or autoimmune diseases.
CC The use of an Fc domain (rather than a Fab domain) can provide a longer
CC half-life or incorporate functions such as Fc receptor binding, protein

CC A binding, complement fixation, and possibly placental transfer. AAA69443
CC to AAA69526 and AAB16955 to AAB18003 represent nucleotide and amino acid
CC sequences used in the exemplification of the present invention.
XX
SQ Sequence 8 AA;

Query Match 70.7%; Score 41; DB 21; Length 8;
Best Local Similarity 100.0%; Pred. No. 9.3e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NTLKTPRV 8
||||||||
Db 1 NTLKTPRV 8

RESULT 6
ABB73360
ID ABB73360 standard; Peptide; 8 AA.
XX
AC ABB73360;
XX
DT 05-APR-2002 (first entry)
XX
DE Exemplary pharmacologically active peptide SEQ ID NO:1099.
XX
KW Modified peptide; mimetic; Fc domain; fusion; immunoglobulin G; IgG;
KW EPO; erythropoietin; TPO; tumour necrosis factor alpha inhibitor;
KW TNF-alpha inhibitor; interleukin 1 antagonist; IL-1 antagonist; TMP;
KW TPO mimetic peptide; EPO mimetic peptide; EMP; VEGF antagonist;
KW MMP inhibitor; antiinflammatory; antitumour; immunosuppressive;
KW cytostatic; antirheumatic; antiarthritic; antidiabetic; ophthalmological;
KW antianaemic; anorectic; antiinfertility; haemostatic; dermatological;
KW neuroprotective; inflammatory disease; autoimmune disease; tumour growth;
KW cancer; rheumatoid arthritis; diabetic retinopathy; infertility; obesity;
KW sleep disorder; neurological degenerative disease; anaemia;
KW thrombocytopaenia; metastatic tumour; systemic lupus erythematosus;
KW Fanconi's syndrome.
XX
OS Synthetic.
XX
PN WO200183525-A2.
XX
PD 08-NOV-2001.
XX
PF 02-MAY-2001; 2001WO-US14310.
XX
PR 03-MAY-2000; 2000US-0563286.
XX
PA (AMGE-) AMGEN INC.
XX
PI Feige U, Liu C, Cheetham JC, Boone TC, Gudas JM;
XX
DR WPI; 2002-130313/17.
XX
PT Novel vehicle-peptide molecule or its multimers useful for treating
PT inflammatory and autoimmune diseases, cancer, rheumatoid arthritis,
PT diabetic retinopathy, obesity, sleep disorders and infertility -
XX
PS Claim 39; Page 62; 176pp; English.
XX
CC The present invention describes a vehicle-peptide molecule (I) or its
CC multimers. (I) can have antiinflammatory, antitumour, immunosuppressive,
CC cytostatic, antirheumatic, antiarthritic, antidiabetic, ophthalmological,
CC antianaemic, anorectic, antiinfertility, haemostatic, dermatological and
CC neuroprotective activities. (I) can be used as a therapeutic or
CC prophylactic agent as well as for screening purposes. (I) is useful for
CC diagnosing diseases characterised by dysfunction of their associated
CC protein of interest, for identifying normal or abnormal proteins of
CC interest, as a part of diagnostic kit to detect the presence of their
CC proteins of interest in a biological sample. Additionally, (I) is useful
CC for treating inflammatory and autoimmune diseases, tumour growth, cancer,
CC rheumatoid arthritis, diabetic retinopathy, obesity, sleep disorders,
CC infertility, and neurological degenerative diseases. (I), comprising
CC EPO-mimetic compounds are useful for treating disorders characterised by
CC low red blood cell levels such as anaemia. The TPO-mimetic comprising
CC compounds are useful for treating conditions that involve an existing
CC megakaryocyte/platelet deficiency or an expected megakaryocyte/platelet
CC deficiency, such as thrombocytopaenia, aplastic anaemia, metastatic
CC tumour which result in thrombocytopaenia, systemic lupus erythematosus,
CC and Fanconi's syndrome. ABB72403 to ABB73426 and ABL35695 to ABL35777
CC represent amino acid and nucleic acid sequences used in the
CC exemplification of the present invention.
XX
SQ Sequence 8 AA;

Query Match 70.7%; Score 41; DB 23; Length 8;
Best Local Similarity 100.0%; Pred. No. 9.3e+05;
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 NTLKTPRV 8
||||||||
Db 1 NTLKTPRV 8

RESULT 7
ABP77111
ID ABP77111 standard; Protein; 372 AA.
XX
AC ABP77111;
XX
DT 07-MAR-2003 (first entry)
XX
DE N. gonorrhoeae amino acid sequence SEQ ID 752.
XX
KW Antibacterial; infection; vaccine; gene therapy.
XX
OS Neisseria gonorrhoeae.
XX
PN WO200279243-A2.
XX
PD 10-OCT-2002.
XX
PF 12-FEB-2002; 2002WO-IB02069.
XX
PR 12-FEB-2001; 2001GB-0003424.
XX
PA (CHIR-) CHIRON SPA.
XX
PI Fontana MR, Pizza M, Masignani V, Monaci E;
XX
DR WPI; 2003-058415/05.
DR N-PSDB; ABZ38081.
XX
PT New protein from Neisseria gonorrheae, useful for the manufacture of a
PT medicament for treating or preventing N. gonorrheae infection -
XX
PS Disclosure; Page 244; 815pp; English.
XX
CC The present invention relates to proteins from Neisseria gonorrhoeae.
CC Also disclosed are the nucleic acid molecules encoding the proteins and
CC antibodies that specifically bind to the proteins. The composition
CC comprising the protein, nucleic acid or antibody is useful for the
CC manufacture of a medicament for treating or preventing N. gonorrhoeae
CC infection, this may be in the form of a vaccine or gene therapy.
CC Sequences given in records ABP76736-ABP81046 represent nucleic acid
CC molecules of the invention.
XX
SQ Sequence 372 AA;

Query Match 65.5%; Score 38; DB 24; Length 372;
Best Local Similarity 70.0%; Pred. No. 62;
Matches 7; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NTLKTPRVGG 10
:||: |||||
Db 182 DTLRHPRVGG 191

```
RESULT 8
AAY11550
ID   AAY11550 standard; Protein; 68 AA.
XX
AC   AAY11550;
XX
DT   16-JUN-1999  (first entry)
XX
DE   Human 5' EST secreted protein SEQ ID NO:202.
XX
KW   Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW   forensic; gene therapy; chromosome mapping; signal peptide;
KW   upstream regulatory sequence; cytokine activity; cell proliferation;
KW   differentiation; haematopoiesis regulation; tissue growth regulation;
KW   reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW   thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS   Homo sapiens.
XX
PN   WO9906439-A2.
XX
PD   11-FEB-1999.
XX
PF   31-JUL-1998;   98WO-IB01233.
XX
PR   01-AUG-1997;   97US-0904468.
XX
PA   (GEST ) GENSET.
XX
PI   Duclert A,  Dumas Milne Edwards J,  Lacroix B;
XX
DR   WPI; 1999-153700/13.
DR   N-PSDB; AAX40268.
XX
PT   New nucleic acids encoding human secreted proteins - obtained from
PT   cDNA libraries derived from liver, lung, large intestine, colon,
PT   thyroid and pancreas tissue
XX
PS   Claim 27; Page 318; 398pp; English.
XX
CC   AAX40251 to AAX40397 represent 5' expressed sequence tags (ESTs) for
CC   human secreted proteins, and encode the proteins given in AAY11533 to
CC   AAY11679, respectively. The proteins given represent the signal peptide
CC   and an N-terminal fragment of a secreted protein. The nucleic acid
CC   sequences can be used for producing secreted human gene products. They
CC   can also be used to develop products for diagnosis and therapy. The
CC   proteins obtained may have cytokine activity, cell
CC   proliferation/differentiation activity, haematopoiesis regulating
CC   activity, tissue growth regulating activity, reproductive hormone
CC   regulating activity, chemotactic/ chemokinetic activity, haemostatic and
CC   thrombolytic activity, receptor/ ligand activity, anti-inflammatory
CC   activity, tumour inhibition activity or other activities. The products
CC   can be used in forensic, gene therapy and chromosome mapping procedures.
CC   The sequences can also be used for obtaining corresponding promoter
CC   sequences. The nucleic acids encoding the signal peptide can be used for
CC   directing extracellular secretion of a polypeptide or the insertion of a
CC   polypeptide into a membrane, or importing a polypeptide into a cell.
XX
SQ   Sequence   68 AA;

  Query Match             63.8%;  Score 37;  DB 20;  Length 68;
  Best Local Similarity   63.6%;  Pred. No. 17;
  Matches    7;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 TLKTPRVGGXA 12
              || | |:|| |
Db          9 TLSTERIGGAA 19


RESULT 9
AAY11742
ID   AAY11742 standard; Protein; 82 AA.
XX
AC   AAY11742;
XX
DT   18-JUN-1999  (first entry)
XX
DE   Human 5' EST secreted protein SEQ ID No: 342.
XX
KW   Human; secreted protein; EST; expressed sequence tag; diagnosis;
KW   forensic; gene therapy; chromosome mapping; signal peptide; prostate;
KW   upstream regulatory sequence; cytokine activity; cell proliferation;
KW   differentiation; haematopoiesis regulation; tissue growth regulation;
KW   reproductive hormone regulation; chemotactic; chemokinetic; haemostatic;
KW   thrombolytic; anti-inflammatory; tumour inhibition.
XX
OS   Homo sapiens.
XX
PN   WO9906550-A2.
XX
PD   11-FEB-1999.
XX
PF   31-JUL-1998;   98WO-IB01232.
XX
PR   01-AUG-1997;   97US-0905144.
XX
PA   (GEST ) GENSET.
XX
PI   Duclert A,  Dumas Milne Edwards J,  Lacroix B;
XX
DR   WPI; 1999-153780/13.
DR   N-PSDB; AAX40464.
XX
PT   New isolated prostate-derived nucleic acids - used to develop
PT   products which may have cytokine, immune regulatory, haematopoiesis
PT   regulating, anti-inflammatory or tumour inhibition activity
XX
PS   Claim 34; Page 517-518; 675pp; English.
XX
CC   AAX40438 to AAX40715 represent 5' expressed sequence tags (ESTs) for
CC   human secreted proteins expressed in prostate, and encode the proteins
CC   given in AAY11716 to AAY11993 respectively. The proteins given represent
CC   the signal peptide and an N-terminal fragment of a secreted protein. The
CC   nucleic acid sequences can be used for producing secreted human gene
CC   products. They can also be used to develop products for diagnosis and
CC   therapy. The proteins obtained may have cytokine activity, cell
CC   proliferation and differentiation activity, haematopoiesis regulating
CC   activity, tissue growth regulating activity, reproductive hormone
CC   regulating activity, chemotactic/chemokinetic activity, haemostatic and
CC   thrombolytic activity, receptor/ligand activity, anti-inflammatory
CC   activity, tumour inhibition activity or other activities. The products
CC   can be used in forensic, gene therapy and chromosome mapping procedures.
CC   The sequences can also be used for obtaining corresponding promoter
CC   sequences. The nucleic acids encoding the signal peptides can be used for
CC   directing extracellular secretion of a polypeptide or the insertion of a
CC   polypeptide into a membrane, or importing a polypeptide into a cell.
XX
SQ   Sequence   82 AA;

  Query Match             63.8%;  Score 37;  DB 20;  Length 82;
  Best Local Similarity   63.6%;  Pred. No. 20;
  Matches    7;  Conservative    1;  Mismatches    3;  Indels    0;  Gaps    0;

Qy          2 TLKTPRVGGXA 12
              || | |:|| |
Db          9 TLSTERIGGAA 19


RESULT 10
ABP66299
ID   ABP66299 standard; Protein; 388 AA.
XX
AC   ABP66299;
XX
```

DT 19-NOV-2002 (first entry)
XX
DE Bifidobacterium longum NCC2705 ORF amino acid sequence SEQ ID NO:1043.
XX
KW Bifidobacterium longum NCC2705; Bifidobacterium; bacterial;
KW antidiarrheic; antibacterial; inhibitor of Salmonella; detection;
KW identification; lactic acid bacterium; diarrhoea; pathogenic bacteria;
KW rotavirus; food composition; pharmaceutical composition.
XX
OS Bifidobacterium longum.
XX
PN EP1227152-A1.
XX
PD 31-JUL-2002.
XX
PF 30-JAN-2001; 2001EP-0102050.
XX
PR 30-JAN-2001; 2001EP-0102050.
XX
PA (NEST) SOC PROD NESTLE SA.
XX
DR WPI; 2002-668397/72.
XX
PT Novel polynucleotide comprising Bifidobacterium genome sequence useful
PT as a probe or primer for detecting and/or identifying Bifidobacterium
PT longum in a biological sample -
XX
PS Claim 3; SEQ ID 1043; 80pp; English.
XX
CC The present invention describes a polynucleotide (I) comprising a
CC sequence of a Bifidobacterium genome selected from the nucleotide
CC sequences given in ABQ81842 and ABQ81843, or a sequence exhibiting at
CC least 90% identity or which hybridises with the sequences given in
CC ABQ81842 and ABQ81843. Also described is a polynucleotide (II) encoding
CC a fusion protein, comprising a sequence selected from 1097 sequences
CC given in ABP65258 to ABP66354 ligated in frame to a polynucleotide
CC encoding a heterologous polypeptide. (I) has antidiarrheic and
CC antibacterial activities, and can be used as an inhibitor of Salmonella.
CC (I) (which is a probe) is useful for the detection and/or identification
CC of Bifidobacterium longum in a biological sample. A carrier containing
CC the lactic acid bacterium Bifidobacterium longum NCC2705 (CNCM I-2618)
CC can be used for preventing and/or treating diarrhoea brought about by
CC pathogenic bacteria and/or rotavirus. The carrier is a food composition
CC selected from milk, yogurt, curd, cheese, fermented milks, milk based
CC fermented products, ice-creams, fermented cereal based products, milk
CC based powders, infant formula, pet food or a pharmaceutical composition
CC selected from tablets, liquid bacterial suspensions, dried oral
CC supplement, wet oral supplement, dry tube feeding or wet tube feeding.
CC (I) is useful in DNA arrays or chips to carry out analysis of the
CC expression of the Bifidobacterium gene. ABQ81844 to ABQ81850 represent
CC Bifidobacterium related nucleotide sequences given in the Sequence
CC Listing from the present invention but not mentioned further within the
CC specification.
CC N.B. The sequence data for this patent is not represented in the printed
CC specification but is based on sequence information supplied by the
CC European Patent Office.
XX
SQ Sequence 388 AA;

Query Match 63.8%; Score 37; DB 23; Length 388;
Best Local Similarity 60.0%; Pred. No. 1e+02;
Matches 6; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NTLKTPRVGG 10
:|: |||:||
Db 2 HTIPTPRMGG 11

RESULT 11
AAU48931
ID AAU48931 standard; Protein; 92 AA.
XX
AC AAU48931;
XX
DT 27-FEB-2002 (first entry)
XX
DE Propionibacterium acnes immunogenic protein #9827.
XX
KW SAPHO syndrome; synovitis; acne; pustulosis; hypertosis; osteomyelitis;
KW uveitis; endophthalmitis; bone; joint; central nervous system; ELISA;
KW inflammatory lesion; acne vulgaris; enzyme linked immunosorbent assay;
KW dermatological; osteopathic; neuroprotectant.
XX
OS Propionibacterium acnes.
XX
PN WO200181581-A2.
XX
PD 01-NOV-2001.
XX
PF 20-APR-2001; 2001WO-US12865.
XX
PR 21-APR-2000; 2000US-199047P.
PR 02-JUN-2000; 2000US-208841P.
PR 07-JUL-2000; 2000US-216747P.
XX
PA (CORI-) CORIXA CORP.
XX
PI Skeiky YAW, Persing DH, Mitcham JL, Wang SS, Bhatia A;
PI L'maisonneuve J, Zhang Y, Jen S, Carter D;
XX
DR WPI; 2001-616774/71.
DR N-PSDB; AAS59543.
XX
PT Propionibacterium acnes polypeptides and nucleic acids useful for
PT vaccinating against and diagnosing infections, especially useful for
PT treating acne vulgaris -
XX
PS Example 1; SEQ ID No 10126; 1069pp; English.
XX
CC Sequences AAU39105-AAU68017 represent Propionibacterium acnes immunogenic
CC polypeptides. The proteins and their associated DNA sequences are used in
CC the treatment, prevention and diagnosis of medical conditions caused by
CC P. acnes. The disorders include SAPHO syndrome (synovitis, acne,
CC pustulosis, hypertosis and osteomyelitis), uveitis and endophthalmitis.
CC P. acnes is also involved in infections of bone, joints and the central
CC nervous system, however it is particularly involved in the inflammatory
CC lesions associated with acne vulgaris. A method for detecting the
CC presence or absence of P. acnes in a patient comprises contacting a
CC sample with a binding agent that binds to the proteins of the invention
CC and determining the amount of bound protein in the sample. The
CC polypeptides may be used as antigens in the production of antibodies
CC specific for P. acnes proteins. These antibodies can be used to
CC downregulate expression and activity of P. acnes polypeptides and
CC therefore treat P. acnes infections. The antibodies may also be used as
CC diagnostic agents for determining P. acnes presence, for example, by
CC enzyme linked immunosorbent assay (ELISA).
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 92 AA;

Query Match 62.1%; Score 36; DB 22; Length 92;
Best Local Similarity 87.5%; Pred. No. 35;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 5 TPRVGGXA 12
|||||| |
Db 24 TPRVGGVA 31

RESULT 12
AAM93750
ID AAM93750 standard; Protein; 140 AA.
XX
AC AAM93750;

XX
DT 06-NOV-2001 (first entry)
XX
DE Human polypeptide, SEQ ID NO: 3731.
XX
KW Human; full length cDNA; cDNA synthesis; oligo-capping.
XX
OS Homo sapiens.
XX
PN EP1130094-A2.
XX
PD 05-SEP-2001.
XX
PF 07-JUL-2000; 2000EP-0114089.
XX
PR 08-JUL-1999; 99JP-0194486.
PR 11-JAN-2000; 2000JP-0118774.
PR 02-MAY-2000; 2000JP-0183765.
XX
PA (HELI-) HELIX RES INST.
XX
PI Ota T, Nishikawa T, Isogai T, Hayashi K, Ishii S, Kawai Y;
PI Wakamatsu A, Sugiyama T, Nagai K, Kojima S, Otsuki T, Koga H;
XX
DR WPI; 2001-524255/58.
DR N-PSDB; AAK94702.
XX
PT 830 Primers useful for synthesizing full length cDNA clones and their
PT use in genetic manipulation -
XX
PS Claim 8; SEQ ID NO 3731; 1380pp + sequence listing; English.
XX
CC The invention relates to primers for synthesising full length cDNA
CC clones. 830 cDNA molecules encoding a human protein have been
CC isolated and nucleotide sequences of 5'- and 3'-ends of the cDNA
CC molecules have been determined. Primers for synthesising the full length
CC cDNA are useful for clarifying the function of the protein encoded by
CC the cDNA. The full length clones were obtained by construction of full
CC length enriched cDNA libraries that were synthesised by the oligo-capping
CC method. The primers enable the production of the full length cDNA easily
CC without any special methods. The present sequence is a polypeptide
CC encoded by a full length human cDNA of the invention.
CC Note: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in CD-ROM format directly from EPO.
XX
SQ Sequence 140 AA;

Query Match 62.1%; Score 36; DB 22; Length 140;
Best Local Similarity 58.3%; Pred. No. 54;
Matches 7; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1 NTLKTPRVGGXA 12
:||: || || |
Db 36 STLRPPRPGGDA 47

RESULT 13
ABB54460
ID ABB54460 standard; Protein; 256 AA.
XX
AC ABB54460;
XX
DT 16-MAY-2002 (first entry)
XX
DE Lactococcus lactis protein ylfH.
XX
KW Biosynthesis; biodegradation; lactic bacterium; yogurt; cheese.
XX
OS Lactococcus lactis IL1403.
XX
PN FR2807446-A1.
XX
PD 12-OCT-2001.
XX
PF 11-APR-2000; 2000FR-0004630.
XX
PR 11-APR-2000; 2000FR-0004630.
XX
PA (INRG) INRA INST NAT RECH AGRONOMIQUE.
XX
PI Bolotine A, Sorokine A, Renault P, Ehrlich SD;
XX
DR WPI; 2002-043418/06.
XX
PT New nucleotide sequence useful in the identification or Lactococcus
PT lactis and related species -
XX
PS Claim 6; SEQ ID No 1162; 2504pp; French.
XX
CC The present invention is related to a Lactococcus lactis nucleotide
CC sequence (ABA90521) and related proteins (ABB53300-ABB55621). The
CC nucleic acid sequence is useful in the detection and/or amplification of
CC nucleic acid sequence, particularly to identify Lactococcus lactis or
CC related species. The proteins of the invention are useful for the
CC biosynthesis or biodegradation of a composition of interest. The
CC invention helps research in lactic bacteria, particularly useful in the
CC production of yogurt and cheese.
CC Note: The sequence data for this patent is based on equivalent patent
CC WO200177334 (published 18-OCT-2001) which is available in electronic
CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 256 AA;

Query Match 62.1%; Score 36; DB 23; Length 256;
Best Local Similarity 87.5%; Pred. No. 1e+02;
Matches 7; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1 NTLKTPRV 8
|| |||||
Db 47 NTTKTPRV 54

RESULT 14
AAG06393
ID AAG06393 standard; Protein; 319 AA.
XX
AC AAG06393;
XX
DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 3150.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.

PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.
PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.

PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 62.1%; Score 36; DB 21; Length 319;
Best Local Similarity 77.8%; Pred. No. 1.3e+02;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 2 TLKTPRVGG 10
|||.|.|||
Db 60 TLKVPTVGG 68

RESULT 15
AAG06392
ID AAG06392 standard; Protein; 323 AA.
XX
AC AAG06392;
XX
DT 17-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 3149.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-0301439.
XX
PR 25-FEB-1999; 99US-0121825.
PR 05-MAR-1999; 99US-0123180.
PR 09-MAR-1999; 99US-0123548.
PR 23-MAR-1999; 99US-0125788.
PR 25-MAR-1999; 99US-0126264.
PR 29-MAR-1999; 99US-0126785.
PR 01-APR-1999; 99US-0127462.
PR 06-APR-1999; 99US-0128234.
PR 08-APR-1999; 99US-0128714.
PR 16-APR-1999; 99US-0129845.
PR 19-APR-1999; 99US-0130077.
PR 21-APR-1999; 99US-0130449.
PR 23-APR-1999; 99US-0130510.
PR 23-APR-1999; 99US-0130891.
PR 28-APR-1999; 99US-0131449.
PR 30-APR-1999; 99US-0132048.
PR 30-APR-1999; 99US-0132407.
PR 04-MAY-1999; 99US-0132484.
PR 05-MAY-1999; 99US-0132485.
PR 06-MAY-1999; 99US-0132486.
PR 06-MAY-1999; 99US-0132487.
PR 07-MAY-1999; 99US-0132863.
PR 11-MAY-1999; 99US-0134256.
PR 14-MAY-1999; 99US-0134218.
PR 14-MAY-1999; 99US-0134219.
PR 14-MAY-1999; 99US-0134221.
PR 14-MAY-1999; 99US-0134370.
PR 18-MAY-1999; 99US-0134768.
PR 19-MAY-1999; 99US-0134941.
PR 20-MAY-1999; 99US-0135124.
PR 21-MAY-1999; 99US-0135353.
PR 24-MAY-1999; 99US-0135629.
PR 25-MAY-1999; 99US-0136021.
PR 27-MAY-1999; 99US-0136392.
PR 28-MAY-1999; 99US-0136782.
PR 01-JUN-1999; 99US-0137222.
PR 03-JUN-1999; 99US-0137528.
PR 04-JUN-1999; 99US-0137502.
PR 07-JUN-1999; 99US-0137724.
PR 08-JUN-1999; 99US-0138094.
PR 10-JUN-1999; 99US-0138540.
PR 10-JUN-1999; 99US-0138847.
PR 14-JUN-1999; 99US-0139119.
PR 16-JUN-1999; 99US-0139452.
PR 16-JUN-1999; 99US-0139453.
PR 17-JUN-1999; 99US-0139492.
PR 18-JUN-1999; 99US-0139454.
PR 18-JUN-1999; 99US-0139455.
PR 18-JUN-1999; 99US-0139456.
PR 18-JUN-1999; 99US-0139457.
PR 18-JUN-1999; 99US-0139458.
PR 18-JUN-1999; 99US-0139459.
PR 18-JUN-1999; 99US-0139460.
PR 18-JUN-1999; 99US-0139461.
PR 18-JUN-1999; 99US-0139462.
PR 18-JUN-1999; 99US-0139463.
PR 18-JUN-1999; 99US-0139750.
PR 18-JUN-1999; 99US-0139763.
PR 21-JUN-1999; 99US-0139817.
PR 22-JUN-1999; 99US-0139899.
PR 23-JUN-1999; 99US-0140353.
PR 23-JUN-1999; 99US-0140354.
PR 24-JUN-1999; 99US-0140695.
PR 28-JUN-1999; 99US-0140823.
PR 29-JUN-1999; 99US-0140991.
PR 30-JUN-1999; 99US-0141287.
PR 01-JUL-1999; 99US-0141842.
PR 01-JUL-1999; 99US-0142154.
PR 02-JUL-1999; 99US-0142055.
PR 06-JUL-1999; 99US-0142390.
PR 08-JUL-1999; 99US-0142803.
PR 09-JUL-1999; 99US-0142920.
PR 12-JUL-1999; 99US-0142977.
PR 13-JUL-1999; 99US-0143542.
PR 14-JUL-1999; 99US-0143624.
PR 15-JUL-1999; 99US-0144005.
PR 16-JUL-1999; 99US-0144085.
PR 16-JUL-1999; 99US-0144086.
PR 19-JUL-1999; 99US-0144325.
PR 19-JUL-1999; 99US-0144331.
PR 19-JUL-1999; 99US-0144332.
PR 19-JUL-1999; 99US-0144333.
PR 19-JUL-1999; 99US-0144334.
PR 19-JUL-1999; 99US-0144335.
PR 20-JUL-1999; 99US-0144352.
PR 20-JUL-1999; 99US-0144632.
PR 20-JUL-1999; 99US-0144884.
PR 21-JUL-1999; 99US-0144814.
PR 21-JUL-1999; 99US-0145086.
PR 21-JUL-1999; 99US-0145088.
PR 22-JUL-1999; 99US-0145085.
PR 22-JUL-1999; 99US-0145087.

PR 22-JUL-1999; 99US-0145089.
PR 22-JUL-1999; 99US-0145192.
PR 23-JUL-1999; 99US-0145145.
PR 23-JUL-1999; 99US-0145218.
PR 23-JUL-1999; 99US-0145224.
PR 26-JUL-1999; 99US-0145276.
PR 27-JUL-1999; 99US-0145913.
PR 27-JUL-1999; 99US-0145918.
PR 27-JUL-1999; 99US-0145919.
PR 28-JUL-1999; 99US-0145951.
PR 02-AUG-1999; 99US-0146386.
PR 02-AUG-1999; 99US-0146388.
PR 02-AUG-1999; 99US-0146389.
PR 03-AUG-1999; 99US-0147038.
PR 04-AUG-1999; 99US-0147204.
PR 04-AUG-1999; 99US-0147302.
PR 05-AUG-1999; 99US-0147192.
PR 05-AUG-1999; 99US-0147260.
PR 06-AUG-1999; 99US-0147303.
PR 06-AUG-1999; 99US-0147416.
PR 09-AUG-1999; 99US-0147493.
PR 09-AUG-1999; 99US-0147935.
PR 10-AUG-1999; 99US-0148171.
PR 11-AUG-1999; 99US-0148319.
PR 12-AUG-1999; 99US-0148341.
PR 13-AUG-1999; 99US-0148565.
PR 13-AUG-1999; 99US-0148684.
PR 16-AUG-1999; 99US-0149368.
PR 17-AUG-1999; 99US-0149175.
PR 18-AUG-1999; 99US-0149426.
PR 20-AUG-1999; 99US-0149722.
PR 20-AUG-1999; 99US-0149723.
PR 20-AUG-1999; 99US-0149929.
PR 23-AUG-1999; 99US-0149902.
PR 23-AUG-1999; 99US-0149930.
PR 25-AUG-1999; 99US-0150566.
PR 26-AUG-1999; 99US-0150884.
PR 27-AUG-1999; 99US-0151065.
PR 27-AUG-1999; 99US-0151066.
PR 27-AUG-1999; 99US-0151080.
PR 30-AUG-1999; 99US-0151303.
PR 31-AUG-1999; 99US-0151438.
PR 01-SEP-1999; 99US-0151930.
PR 07-SEP-1999; 99US-0152363.
PR 10-SEP-1999; 99US-0153070.
PR 13-SEP-1999; 99US-0153758.
PR 15-SEP-1999; 99US-0154018.
PR 16-SEP-1999; 99US-0154039.
PR 20-SEP-1999; 99US-0154779.
PR 22-SEP-1999; 99US-0155139.
PR 23-SEP-1999; 99US-0155486.
PR 24-SEP-1999; 99US-0155659.
PR 28-SEP-1999; 99US-0156458.
PR 29-SEP-1999; 99US-0156596.
PR 04-OCT-1999; 99US-0157117.
PR 05-OCT-1999; 99US-0157753.
PR 06-OCT-1999; 99US-0157865.
PR 07-OCT-1999; 99US-0158029.
PR 08-OCT-1999; 99US-0158232.
PR 12-OCT-1999; 99US-0158369.
PR 13-OCT-1999; 99US-0159293.
PR 13-OCT-1999; 99US-0159294.
PR 13-OCT-1999; 99US-0159295.
PR 14-OCT-1999; 99US-0159329.
PR 14-OCT-1999; 99US-0159330.
PR 14-OCT-1999; 99US-0159331.
PR 14-OCT-1999; 99US-0159637.
PR 14-OCT-1999; 99US-0159638.
PR 18-OCT-1999; 99US-0159584.
PR 21-OCT-1999; 99US-0160741.
PR 21-OCT-1999; 99US-0160767.
PR 21-OCT-1999; 99US-0160768.
PR 21-OCT-1999; 99US-0160770.
PR 21-OCT-1999; 99US-0160814.
PR 21-OCT-1999; 99US-0160815.
PR 22-OCT-1999; 99US-0160980.
PR 22-OCT-1999; 99US-0160981.
PR 22-OCT-1999; 99US-0160989.
PR 25-OCT-1999; 99US-0161404.
PR 25-OCT-1999; 99US-0161405.
PR 25-OCT-1999; 99US-0161406.
PR 26-OCT-1999; 99US-0161359.
PR 26-OCT-1999; 99US-0161360.
PR 26-OCT-1999; 99US-0161361.
PR 28-OCT-1999; 99US-0161920.
PR 28-OCT-1999; 99US-0161992.
PR 28-OCT-1999; 99US-0161993.
PR 29-OCT-1999; 99US-0162142.

Query Match 62.1%; Score 36; DB 21; Length 323;
Best Local Similarity 77.8%; Pred. No. 1.3e+02;
Matches 7; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
Qy          2 TLKTPRVGG 10
              ||| | |||
Db         64 TLKVPTVGG 72
```

Search completed: August 28, 2003, 18:34:28
Job time : 38.0909 secs